Technical Analysis for CARA - Cara Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
18.91 | 6.84% | 1.21 |
CARA closed up 6.84 percent on Tuesday, April 23, 2019, on 1.28 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Down |
| See historical CARA trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 200 DMA | Bullish | 0.00% | |
| Crossed Above 50 DMA | Bullish | 0.00% | |
| Stochastic Buy Signal | Bullish | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Fell Below 50 DMA | Bearish | 6.84% | |
| Lower Bollinger Band Walk | Weakness | 6.84% | |
| Inside Day | Range Contraction | 6.84% | |
| Below Lower BB | Weakness | 6.84% | |
| Lower Bollinger Band Touch | Weakness | 6.84% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2019-03-12
- Sector: Healthcare
- Industry: Biotechnology
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat pain. Its products include intravenous CR845 that has completed Phase II clinical trials for the treatment of acute postoperative pain in adult patients; Oral CR845, which is in Phase I clinical trials to treat acute and chronic pain; and CR701 that is in preclinical trials for treating neuropathic and inflammatory pain. The company was founded in 2004 and is based in Shelton, Connecticut.
Chemistry Health Biopharmaceutical Pain Clinical Trial Piperidines Amines Mesoblast Trevena Inc
Chemistry Health Biopharmaceutical Pain Clinical Trial Piperidines Amines Mesoblast Trevena Inc
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more CARA news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 24.3 |
| 52 Week Low | 11.5 |
| Average Volume | 671,515 |
| 200-Day Moving Average | 18.2813 |
| 50-Day Moving Average | 18.1982 |
| 20-Day Moving Average | 19.273 |
| 10-Day Moving Average | 19.054 |
| Average True Range | 0.8859 |
| ADX | 22.37 |
| +DI | 21.9238 |
| -DI | 25.0163 |
| Chandelier Exit (Long, 3 ATRs ) | 18.1923 |
| Chandelier Exit (Short, 3 ATRs ) | 19.9777 |
| Upper Bollinger Band | 20.7048 |
| Lower Bollinger Band | 17.8412 |
| Percent B (%b) | 0.37 |
| BandWidth | 14.858092 |
| MACD Line | 0.055 |
| MACD Signal Line | 0.3128 |
| MACD Histogram | -0.2578 |
| Fundamentals | Value |
|---|---|
| Market Cap | 616.1 Million |
| Num Shares | 32.6 Million |
| EPS | -2.28 |
| Price-to-Earnings (P/E) Ratio | -8.29 |
| Price-to-Sales | 424.16 |
| Price-to-Book | 3.54 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 21.09 | ||||
| Resistance 3 (R3) | 20.92 | 20.04 | 20.72 | ||
| Resistance 2 (R2) | 20.04 | 19.48 | 20.12 | 20.60 | |
| Resistance 1 (R1) | 19.47 | 19.14 | 19.76 | 19.64 | 20.48 |
| Pivot Point | 18.59 | 18.59 | 18.73 | 18.67 | 18.59 |
| Support 1 (S1) | 18.02 | 18.03 | 18.31 | 18.19 | 17.34 |
| Support 2 (S2) | 17.14 | 17.69 | 17.22 | 17.22 | |
| Support 3 (S3) | 16.57 | 17.14 | 17.10 | ||
| Support 4 (S4) | 16.74 |
